Scroll for more

news

Feb 20, 2018 articles

Targeted protein degraders are redefining how small molecules look and act

The new modality promises to open up the human proteome to drug developers, but first they will need to work out the rules.

Feb 13, 2018 articles

Digital Innovators: Q&A with BenevolentAI founder and chairman Ken Mulvany

Last year BenevolentAI was identified as one of 50 of the freshest and most inspiring digital companies using technology and innovation to shake up their sectors in our Digital Innovators Power List. Following a public vote and after careful consideration by supporting partners and judges, it was named as one of the top 10 Digital Innovators. Later this year two of these companies will be identified as a "life changer" or a "market transformer"

Feb 10, 2018 articles

BBC PODCASTS | The Shock of the New: Relationship between science, business and the consumer

Listen to Jackie Hunter taking part to the BBC podcast with Evan Davis to discuss the relationship between three important pillars of modern society: science, business and the consumer. Is the public right to be suspicious of business and the science it's selling? Why do some us fear GM foods, nanotechnology, AI and gene editing?

Oct 3, 2017 articles

How Close Are We to Curing ALS? A Review of Biotech’s Efforts

Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)

Aug 31, 2017 articles

This AI unicorn is disrupting the pharma industry in a big way

WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.

Aug 22, 2017 articles

BenevolentAI poaches drug discovery executive from GlaxoSmithKline

FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.

Aug 22, 2017 announcements

BenevolentAI hires Head of GSK Discovery Performance Unit as VP Drug discovery

BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.

Jul 7, 2017 articles

Machine Learning and the march towards precision medicine

Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.

Jul 5, 2017 articles

Could AI help treat Motor Neurone Disease?

We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.

May 25, 2017 announcements

AI enabled research shows delay in onset of motor neurone disease

Sheffield and London, UK - 25 May 2017.  The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.

Apr 26, 2017 articles

9 Computational Drug Discovery Startups Using AI

Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Apr 13, 2017 articles

BenevolentAI to power small molecule drug discovery BenevolentAI to power small molecule drug discovery

This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.

Apr 11, 2017 announcements

BenevolentAI agrees partnership with medical research charity MRC technology

London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.

Mar 20, 2017 articles

BenevolentAI Q&A: Techworld meets Dr Jackie Hunter, CEO of BenevolentBio

An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI

Mar 20, 2017 articles

Machines are Helping Healthcare: An Interview with their Biotech Leader

Hunter is the CEO of BenevolentBio, the life sciences arm of BenevolentAI. Just last fall, the company became the first in Europe to install an Nvidia supercomputer, raked in €93M in funding, and closed an Alzheimer’s drug discovery deal that could be worth up to €750M.

Jan 6, 2017 articles

BenevolentAI gets The Economist thinking on biology and AI

We met with The Economist to discuss how artificial intelligence (AI) and machine learning is helping to crack and transform the scientific method.